Birch Hill Investment Advisors LLC grew its stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 0.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 294,772 shares of the medical equipment provider’s stock after buying an additional 1,240 shares during the period. Zimmer Biomet accounts for 3.0% of Birch Hill Investment Advisors LLC’s holdings, making the stock its 12th biggest position. Birch Hill Investment Advisors LLC owned 0.15% of Zimmer Biomet worth $34,515,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Ingalls & Snyder LLC raised its holdings in shares of Zimmer Biomet by 2.6% during the third quarter. Ingalls & Snyder LLC now owns 19,675 shares of the medical equipment provider’s stock worth $2,304,000 after purchasing an additional 507 shares during the last quarter. Koch Industries Inc. raised its holdings in shares of Zimmer Biomet by 49,697.3% during the second quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock worth $1,033,000 after purchasing an additional 1,038,674 shares during the last quarter. Jensen Investment Management Inc. raised its holdings in shares of Zimmer Biomet by 24.2% during the second quarter. Jensen Investment Management Inc. now owns 5,850 shares of the medical equipment provider’s stock worth $751,000 after purchasing an additional 1,140 shares during the last quarter. Andra AP fonden raised its holdings in shares of Zimmer Biomet by 15.8% during the second quarter. Andra AP fonden now owns 21,300 shares of the medical equipment provider’s stock worth $2,735,000 after purchasing an additional 2,900 shares during the last quarter. Finally, Commerce Bank raised its holdings in shares of Zimmer Biomet by 1.5% during the second quarter. Commerce Bank now owns 218,171 shares of the medical equipment provider’s stock worth $28,013,000 after purchasing an additional 3,142 shares during the last quarter. 86.24% of the stock is owned by institutional investors and hedge funds.

ZBH has been the subject of several recent research reports. Jefferies Group reissued a “buy” rating and set a $136.00 target price on shares of Zimmer Biomet in a report on Friday, November 3rd. Gabelli initiated coverage on shares of Zimmer Biomet in a report on Thursday, August 24th. They set a “buy” rating and a $142.00 target price for the company. Oppenheimer set a $137.00 target price on shares of Zimmer Biomet and gave the stock a “buy” rating in a report on Monday, August 14th. SunTrust Banks set a $136.00 target price on shares of Zimmer Biomet and gave the stock a “buy” rating in a report on Wednesday, November 1st. Finally, Edward Jones raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Thursday, November 9th. Four research analysts have rated the stock with a sell rating, seven have issued a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $133.71.

Zimmer Biomet Holdings Inc (ZBH) traded down $1.40 during mid-day trading on Monday, reaching $113.38. 1,680,500 shares of the company traded hands, compared to its average volume of 1,356,293. The firm has a market capitalization of $22,956.40, a price-to-earnings ratio of 14.05, a PEG ratio of 1.76 and a beta of 1.15. The company has a current ratio of 1.47, a quick ratio of 0.78 and a debt-to-equity ratio of 0.88. Zimmer Biomet Holdings Inc has a 52 week low of $100.81 and a 52 week high of $133.49.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.74 by ($0.02). The firm had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.83 billion. Zimmer Biomet had a net margin of 8.36% and a return on equity of 16.29%. The firm’s quarterly revenue was down .8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.79 EPS. research analysts predict that Zimmer Biomet Holdings Inc will post 8.03 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Zimmer Biomet Holdings Inc (ZBH) Shares Bought by Birch Hill Investment Advisors LLC” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/zimmer-biomet-holdings-inc-zbh-shares-bought-by-birch-hill-investment-advisors-llc/1757950.html.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.